Welcome to our dedicated page for Genprex news (Ticker: GNPX), a resource for investors and traders seeking the latest updates and insights on Genprex stock.
Genprex, Inc. (NASDAQ: GNPX) generates a steady flow of news as a clinical-stage gene therapy company developing treatments for cancer and diabetes. Its updates frequently center on progress in lung cancer trials with Reqorsa Gene Therapy (quaratusugene ozeplasmid) and preclinical advances in its diabetes program, GPX-002.
Investors following GNPX news can expect coverage of clinical trial milestones, such as dose-escalation results, Phase 2 expansion plans, new trial site additions, and peer-reviewed publications from studies like the Acclaim-1 and Acclaim-3 trials in non-small cell and small cell lung cancer. Company releases also highlight regulatory designations, including FDA Fast Track and Orphan Drug status for Reqorsa-based programs.
Another major news theme is preclinical and translational data. Genprex and its collaborators report findings on Reqorsa’s activity in specific lung cancer subtypes, including ALK-EML4-positive NSCLC models, as well as animal data showing TUSC2 upregulation, apoptosis induction, and survival benefits in xenograft studies. For diabetes, news often covers GPX-002 proof-of-concept data in Type 1 and Type 2 diabetes mouse and non-human primate models, including effects on beta-cell function and glucose control.
Genprex also issues corporate and regulatory announcements, such as registered direct offerings, at-the-market programs, warrant-related financings, and patent developments around Reqorsa combinations with PD-1 and PD-L1 antibodies. These items provide context on the company’s capital strategy and intellectual property position.
For readers tracking GNPX, this news stream offers insight into how Genprex’s gene therapy platforms are advancing through research, clinical development, regulatory interactions, and financing activities over time.
Genprex, Inc. (GNPX), a clinical-stage gene therapy company, announced its participation in the Virtual Investor Conference Small and Microcap Showcase on February 4, 2021. CEO Rodney Varner will present an overview, highlighting recent advancements in clinical trials. The event starts at 11 a.m. EST, and the presentation will be available for replay on the company’s website after the conference. Genprex focuses on gene therapies for cancer and diabetes, with its lead product, REQORSA™, currently evaluated for treating non-small cell lung cancer (NSCLC).
Genprex (GNPX), a clinical-stage gene therapy company, will present at the MoneyShow Accredited Investors Virtual Expo from January 26-28, 2021. CEO Rodney Varner is scheduled to provide a company overview and discuss recent advancements in clinical trials on January 28 at 12:25 p.m. EST. The presentation will be available for replay on Genprex's website afterwards. Genprex focuses on innovative therapies for cancer and diabetes, with its lead product candidate, REQORSA™, being evaluated for non-small cell lung cancer and having received Fast Track Designation from the FDA.
Genprex, Inc. (NASDAQ: GNPX) announced its participation in NobleCon17, the annual investor conference, on January 19-20. CEO Rodney Varner will present a company overview, with a focus on advancements in clinical trials, at 3:45 p.m. EST on January 19. A video webcast will be available for replay on the company's website post-conference. Notably, Genprex was highlighted in a recent Channelchek report as the most read research report of 2020. The company focuses on innovative gene therapies, including its lead candidate REQORSA™ for non-small cell lung cancer.
Genprex, Inc. (GNPX) announced successful completion of its first scaled-up clinical-grade manufacturing run of REQORSA™ immunogene therapy, essential for upcoming Acclaim-1 and Acclaim-2 clinical trials targeting non-small cell lung cancer (NSCLC). All specifications have been met, enabling supply delivery to clinical trial sites pending FDA approval. The technology transfer to commercial CDMOs has been successfully completed. The trials aim to evaluate REQORSA in combination with AstraZeneca's Tagrisso® and Merck's Keytruda®, initiating in the first half of 2021.
Genprex (Nasdaq: GNPX) closed a registered direct offering of 3,116,884 shares of common stock at $3.85 per share, yielding gross proceeds of $12 million. The funds will support the Acclaim-1 and Acclaim-2 clinical trials for its gene therapy, REQORSA, in combination with AstraZeneca's Tagrisso and Merck's Keytruda, targeting non-small cell lung cancer. The offering was facilitated by A.G.P./Alliance Global Partners, and no warrants were issued. Net proceeds will be allocated to working capital and corporate purposes.
Genprex, Inc. (Nasdaq: GNPX) has entered into a securities purchase agreement with a healthcare-dedicated institutional investor to sell 3,116,884 shares of its common stock at $3.85 per share. This registered direct offering is priced at-the-market under Nasdaq rules, with no warrants issued. The closing is expected around December 24, 2020, subject to customary conditions. A.G.P./Alliance Global Partners acts as the sole placement agent. The offering is made under an effective shelf registration statement previously filed with the SEC.
Genprex, Inc. (GNPX) has completed the manufacturing scale-up of REQORSA™ immunogene therapy, aimed at supplying the Acclaim-1 and Acclaim-2 clinical trials for non-small cell lung cancer. This production adheres to current Good Manufacturing Practices (cGMP) and includes significant advancements that enhance yield and reduce costs. Upon passing final testing, REQORSA will be stored at controlled temperatures before distribution. These trials will assess REQORSA in combination with AstraZeneca's Tagrisso® and Merck's Keytruda® in early 2021, potentially impacting the $26.3 billion lung cancer therapeutics market.
Genprex, Inc. (NASDAQ: GNPX) announced the successful completion of the technology transfer for its lead drug candidate, REQORSA™. This achievement signifies the first commercial-scale production in a cGMP-compliant facility, previously conducted at a major cancer research institution. The company expects enhanced production reliability and scalability, crucial for their upcoming Acclaim-1 and Acclaim-2 clinical trials involving combinations of REQORSA with Tagrisso® and Keytruda®. This milestone represents a significant step forward in Genprex’s drug development efforts.
Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, will present at the Benzinga Global Small Cap Conference on December 8. CEO Rodney Varner will provide insights on recent advancements in the Acclaim-1 clinical trial. The virtual event aims to connect small-cap companies with investors, offering opportunities for one-on-one engagement. Genprex focuses on developing innovative therapies for cancer and diabetes, particularly through its lead product, REQORSA™, which targets non-small cell lung cancer. Registration for the conference is available online.
Genprex, Inc. (NASDAQ: GNPX) has begun recruitment for its Acclaim-1 clinical trial targeting non-small cell lung cancer (NSCLC). This Phase 1/2 trial will assess the efficacy of REQORSA™ immunogene therapy combined with AstraZeneca's Tagrisso in late-stage NSCLC patients with EGFR mutations. The trial plans to enroll approximately 100 patients across 10 U.S. sites, with an interim analysis after 53 events. Genprex received FDA Fast Track Designation for this trial, enhancing its market potential.
FAQ
What is the current stock price of Genprex (GNPX)?
What is the market cap of Genprex (GNPX)?
